Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-07-31 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication dated July 31, 2024, addressed to stock exchanges and shareholders. It announces the availability of the audio recording of an investor conference call for Q1FY25. The text references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which governs disclosure of material events. The document does not contain any financial data or detailed transcript but only provides a link to the audio recording of the call. This fits the profile of a Call Transcript announcement or related communication. However, since it only announces the availability of the audio recording and does not contain the transcript itself, it is not a full Call Transcript (CT). Given the short length (1219 characters) and the nature of the content, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the call recording availability rather than the transcript or report itself.
2024-07-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's management participation in investor meetings. It explicitly states that no unpublished price sensitive information will be disclosed and that the discussion will be based on publicly available information. There are no financial statements, detailed financial data, or report attachments. The document serves as an announcement of an event rather than a financial report or detailed presentation. Given its brevity (1428 characters) and content, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-31 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated July 31, 2024, announcing the financial results of Mankind Pharma for the quarter ended June 30, 2024 (Q1 FY25). It includes detailed financial performance metrics such as revenue, EBITDA, PAT, EPS, segmental revenue, and operational highlights. The document also mentions an upcoming earnings conference call. The content is typical of an Earnings Release, which is an initial announcement of quarterly financial results with key highlights. The document is over 10,000 characters, indicating it is a full release rather than a brief announcement or a report publication notice. There is no indication that this is a full interim or quarterly report with comprehensive financial statements and analysis, so it does not qualify as an Interim/Quarterly Report (IR). It is also not a transcript, management discussion, or any other category. Therefore, the best classification is Earnings Release (ER). Q1 2025
2024-07-31 English
Investor Presentation
Regulatory Filings
2024-07-31 English
Financial Result Updates
Regulatory Filings
2024-07-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the availability of an audio recording of a conference call held on July 26, 2024. The subject explicitly mentions the conference call related to the acquisition of a 100% stake in Bharat Serums and Vaccines Limited. The letter provides a link to the audio recording and requests the exchanges to take it on record. There is no financial data, report, or detailed transcript included, only a notification about the availability of the conference call recording. This fits the definition of a Call Transcript (CT) related filing, but since it only announces the availability of the recording and does not contain the transcript itself, it is best classified as a Regulatory Filing (RNS) as a general announcement. However, given the specific nature of the content (conference call recording availability), the closest specific category is Call Transcript (CT) with moderate confidence, but due to the short length and nature of the document, Regulatory Filings (RNS) is more appropriate as per the rules.
2024-07-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.